An overview of the pediatric medications for the symptomatic treatment of allergic rhinitis, cough, and cold

Journal of Pharmaceutical Sciences

Volumn 102, Issue 12, 2013, Pages 4213-4229

  Fan, Ying ^a   Ji, Ping ^a   Leonard Segal, Andrea ^a   Sahajwalla, Chandrahas G ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Allergic rhinitis; Clinical Pharmacokinetics; Clinical pharmacology; Cough and cold; Pediatrics; Pharmacodynamics; Pharmacokinetics; Population Pharmacokinetics

Indexed keywords

ADVIL COLD CHILDREN; CETIRIZINE; CICLESONIDE; DECONGESTIVE AGENT; DESLORATADINE; FEXOFENADINE; FLUTICASONE; FLUTICASONE PROPIONATE; HYDROCORTISONE; IBUPROFEN; IBUPROFEN PLUS CHLORPHENIRAMINE PLUS PSEUDOEPHEDRINE; IBUPROFEN PLUS PSEUDOEPHEDRINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; LORATADINE; MOMETASONE FUROATE; MONTELUKAST; MOTRIN COLD CHILDREN; MOTRIN INFANT; OLOPATADINE; PLACEBO; PLASMA PROTEIN; SINGULAR; TETRACOSACTIDE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; AREA UNDER THE CURVE; AUTONOMIC NEUROPATHY; BIOEQUIVALENCE; CHILD CARE; CLINICAL PHARMACOLOGY; COGNITION; COMMON COLD SYMPTOM; COMMON COLD SYMPTOM SYMPTOM; COUGHING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE FUNCTION TEST; EPIPHORA; EPISTAXIS; EVENING DOSAGE; FEVER; HAY FEVER; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INFLUENZA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NASAL PRURITUS; NOSE OBSTRUCTION; OUTCOME ASSESSMENT; PAIN; PALLIATIVE THERAPY; PERENNIAL RHINITIS; PSYCHOMOTOR ACTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT ALLERGY; REVIEW; RHINORRHEA; SINGLE DRUG DOSE; SINUS CONGESTION; SLEEP; SOMNOLENCE; SORE THROAT; SUBCUTANEOUS IMMUNOTHERAPY; SYRUP; TABLET FORMULATION; THROAT IRRITATION; TOOTH PAIN; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ALLERGIC RHINITIS; CLINICAL PHARMACOKINETICS; CLINICAL PHARMACOLOGY; COUGH AND COLD; PEDIATRICS; PHARMACODYNAMICS; PHARMACOKINETICS; POPULATION PHARMACOKINETICS;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; COUGH; DRUG DISCOVERY; HISTAMINE ANTAGONISTS; HUMANS; IBUPROFEN; LEUKOTRIENE ANTAGONISTS; RHINITIS, ALLERGIC, PERENNIAL;

EID: 84888204308     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23720     Document Type: Review

References (85)

1. Dykewicz MS, Fineman S, Skoner DP, Nicklas R, Lee R, Blessing-Moore J, Li JT, Bernstein IL, Berger W, Spector S, Schuller D., 1998. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 81: 478-518.
2. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, Williams H., 2006. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 368: 733-743.
3. Togias A., 2001. Systemic cross-talk between the lung and the nose. Am J Respir Crit Care Med 164: 726-727.
4. Millqvist E, Bende M., 2006. Role of the upper airways in patients with chronic cough. Curr Opin Allergy Clin Immunol 6: 7-11.
5. Chang AB, Harrhy VA, Simpson J, Masters IB, Gibson PG., 2002. Cough, airway inflammation, and mild asthma exacerbation. Arch Dis Child 86: 270-275.
6. Consumer Healthcare Products Association. 2007. Key findings of a national survey on cough medicine use. Accessed July 5, 2013, at: http://www.chpa-info.org/media/resources/r-4510.pdf.
7. U.S. Food and Drug Administration. 2012. Public health advisory: FDA recommends that over-the-counter (OTC) cough and cold products not be used for infants and children under 2 years of age. Accessed July 6, 2013, at: http://www.fda.gov/drugs/drugsafety/ postmarketdrugsafetyinformationforpatientsandproviders/ drugsafetyinformationforheathcareprofessionals/publichealthadvisories/ucm051137. htm.
8. U.S. Food and Drug Administration. 2008. FDA statement following CHPA's announcement on nonprescription over-the-counter cough and cold medicines in children. Accessed July 6, 2013, at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2008/ucm116964.htm.
9. U.S. Food and Drug Administration. 2002. Best Pharmaceuticals for Children Act 2002. Public Law 107-109. Accessed July 6, 2013, at: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=107-cong-public- laws&docid=f:publ109.pdf.
10. U.S. Food and Drug Administration. 1997. Food and Drug Administration Modernization Act of 1997. Accessed July 6, 2013, at: http://www.fda.gov/ downloads/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/ SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/UCM089145.pdf.
11. U.S. Food and Drug Administration. 2003. Pediatric Research Equity Act of 2003. Accessed July 6, 2013, at: http://www.gpo.gov/fdsys/pkg/PLAW-108publ155/ html/PLAW-108publ155.htm.
12. U.S. Food and Drug Administration. 1998. The Pediatric Rule. 63 FR 66632, December 2, 1998. Accessed July 6, 2013, at: http://www.fda.gov/ohrms/dockets/ ac/03/briefing/3927B1-05-1998%20Pediatric%20Rule.pdf.
13. Skoner DP., 2001. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 108: S2-S8.
14. Blaiss MS., 2004. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin 20: 1937-1952.
15. Scadding G., 2008. Optimal management of nasal congestion caused by allergic rhinitis in children: safety and efficacy of medical treatments. Paediatr Drugs 10: 151-162.
16. Cox L, Calderon M, Pfaar O., 2012. Subcutaneous allergen immunotherapy for allergic disease: Examining efficacy, safety and cost-effectiveness of current and novel formulations. Immunotherapy 4: 601-616.
17. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S., 2007. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst RevCD001936.
18. Albert AM, Li M, Victor VJ, Abdullah J, Chui CS, Tsen S, Chun CT, Au T, Hugh HS, Lam S, Hung HK, So K, Michael MH, Chan HM, Alex AW, Leung WK, Iris IH, Chan HS, Christopher CW, Lam WK, Pak PC, Ng C,. 2009. Leukotriene receptor antagonist in the treatment of childhood allergic rhinitis-a randomized placebo-controlled study. Pediatr pulmonol 44: 1085-1092.
19. U.S. Food and Drug Administration. 2012. Advisory Committee for pharmaceutical science and clinical pharmacology meeting briefing information. Accessed July 6, 2013, at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM295209.pdf.
20. U.S. Food and Drug Administration. 2004. Clarinex label. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2004/21300lbl. pdf.
21. U.S. Food and Drug Administration. 2008. Allegra label. Accessed July 2, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/020872s018, 021963s002lbl.pdf.
22. U.S. Food and Drug Administration. 2006. Clinical pharmacology review for NDA 21963. Accessed July 2, 2013, at: http://www.accessdata.fda.gov/drugsatfda- docs/nda/2006/021963s000-ClinPharmR.pdf.
23. U.S. Food and Drug Administration. 2012. Singulair label. Accessed July 6, 2012, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 021409s036lbl.pdf.
24. U.S. Food and Drug Administration. 2000. Claritin label. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2000/20641s7lbl. pdf.
25. U.S. Food and Drug Administration. 2004. Zyrtec label. Accessd July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2004/19835slr016, 21150slr005,30346slr011-zyrtec-lbl.pdf.
26. U.S. Food and Drug Administration. 2010. Patanase label. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 021861s008lbl.pdf.
27. U.S. Food and Drug Administration. 2008. Nasacort AQ label. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/ 020468s024lbl.pdf.
28. U.S. Food and Drug Administration. 2010. Omnaris label. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 022004s005lbl.pdf.
29. U.S. Food and Drug Administration. 2011. Nasonex label. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 020762s044lbl.pdf.
30. U.S. Food and Drug Administration. 1998. Children's Advil label. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/98/20944- Advil-prntlbl.pdf.
31. U.S. Food and Drug Administration. 2011. Advil label. Accessed on July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 018989Orig1s079lbl.pdf.
32. U.S. Food and Drug Administration. 2000. Pediatric Advil label. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2000/ 020812s003lbl.pdf.
33. U.S. Food and Drug Administration. 1999. Children's Motrin label. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/99/ 20-603S002-Ibuprofen-prntlbl.pdf.
34. U.S. Food and Drug Administration. 2010. Motrin IB label. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 019012s046lbl.pdf.
35. U.S. Food and Drug Administration. 2002. Infants' Motrin label. Accessed July 6, 2012 at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2002/ 20603s5lbl.pdf.
36. U.S. Food and Drug Administration. 2002. Children's Advil Cold label. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2002/21373lbl.pdf.
37. U.S. Food and Drug Administration. 2003. Advil Cold & Sinus label. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2003/21374SLR001-Advil-lbl.pdf.
38. U.S. Food and Drug Administration. 2001. Advil Cold and Sinus label. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2001/19771S20lbl.pdf.
39. U.S. Food and Drug Administration. 2000. Clinical pharmacology review for NDA 21128. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda- docs/nda/2000/21-128-CHILDREN'S%20MOTRIN%20COLD%20SUSPENSION-BIOPHARMR.PDF.
40. U.S. Food and Drug Administration. 2004. Medical review for NDA 21587. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2004/21-587-Advil-medr.pdf.
41. U.S. Food and Drug Administration. 2004. Advil Allergy Sinus label. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2004/21441slr001-advil-lbl.pdf.
42. Novak E, Allen PJ., 2007. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics. Pediatr Nurs 33: 64-70.
43. Johnson TN, Tucker GT, Rostami-Hodjegan A., 2008. Development of CYP2D6 and CYP3A4 in the first year of life. Clin Pharmacol Ther 83: 670-671.
44. U.S. Food and Drug Administration. 2002. Review package for NDA 20346/S008. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda- docs/nda/2002/020346-S008-ZYRTEC%20TABLETS.pdf.
45. U.S. Food and Drug Administration. 2000. Draft guidance for industry. Allergic rhinitis: Clinical development programs for drug products. Accessed July 6, 2013, at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM071293.pdf.
46. U.S. Food and Drug Administration. 2003. Guidance for industry: Exposure-response relationship-study design, data analysis, and regulatory applications. Accessed July 6, 2013, at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072109.pdf.
47. U.S. Food and Drug Administration. 2004. Medical review for NDA 21300. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2004/021300s000-Clarinex-MedR.pdf.
48. U.S. Food and Drug Administration. 2004. Clinical pharmacology review for NDA 21300. Accessed December 13, 2013, at: http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2004/021300s000-Clarinex-ClinPharmR.pdf.
49. U.S. Food and Drug Administration. 2004. Medical review for NDA 21563. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2004/021563s000-Clarinex-MedR.pdf.
50. U.S. Food and Drug Administration. 2006. Medical review for NDA 21963. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2006/021963s000-MedR.pdf.
51. U.S. Food and Drug Administration. 2000. Review package for NDA 20872. Accessed July 2, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2000/20-872-Allegra.cfm.
52. Simons FE, Simons KJ., 2005. Levocetirizine: Pharmacokinetics and pharmacodynamics in children age 6 to 11 years. J Allergy Clinic Immunol 116: 355-361.
53. U.S. Food and Drug Administration. 2007. Clinical pharmacology review for NDA 22064. Accessed July 5, 2013, at: http://www.accessdata.fda.gov/drugsatfda- docs/nda/2007/022064s000-ClinPharmR.pdf.
54. U.S. Food and Drug Administration. 2011. Xyzal label. Accessed July 5, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/022064s020, 022157s007lbl.pdf.
55. U.S. Food and Drug Administration. 2009. Clinical pharmacology review for NDA 22064, S017. Accessed July 6, 2013, at: http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/UCM188184.pdf.
56. U.S. Food and Drug Administration. 2000. Clinical pharmacology review for NDA 20641 SE5-007. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2000/20-641S007-Loratadine-biopharmr.pdf.
57. U.S. Food and Drug Administration. 2000. Medical review for NDA 20641 SE5-007. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda- docs/nda/2000/20-641S007-Loratadine-medr.pdf.
58. U.S. Food and Drug Administration. 2009. Medical review for NDA 21861 SE5-002. Accessed July 6, 2013, at: http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/UCM289256.pdf.
59. U.S. Food and Drug Administration. 1998. Review package for NDA 19835/S005. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda- docs/nda/98/19835-S005-Zyrtec.pdf.
60. U.S. Food and Drug Administration. 2008. Medical review NDA 20468-S24. Accessed July 6, 2013, at: http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/UCM226045.pdf.
61. Weinstein S, Qaqundah P, Georges G, Nayak A., 2009. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in children aged 2 to 5 years with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled study with an open-label extension. Ann Allergy Asthma Immunol 102: 339-347.
62. Nayak AS, Ellis MH, Gross GN, Mendelson LM, Schenkel EJ, Lanier BQ, Simpson B, Mullin ME, Smith JA., 1998. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. J Allergy Clin Immunol 101: 157-162.
63. U.S. Food and Drug Administration. 2007. Medical review for NDA 22124. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2007/022124s000-MedR.pdf.
64. Meltzer EO, Berger WE, Berkowitz RB, Bronsky EA, Dvorin DJ, Finn AF, Galant SP, Grossman J, Hampel FC, Ratner PH, Ruff ME, Schenkel EJ, Segal AT, Segall N, Stewart GE, Tripathy I, Skoner DP, Anolik R, Dockhorn RJ, van BJ, Mesarina-Wicki B, Nolop K., 1999. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol 104: 107-114.
65. Dibildox J., 2001. Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: results of recent clinical trials. J Allergy Clin Immunol 108: S54-S58.
66. U.S. Food and Drug Administration. 2002. Clinical pharmacology review for NDA 21373. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda- docs/nda/2002/21-373-Ibuprofen%20Pseudoephedrine-biopharmr.pdf.
67. U.S. Food and Drug Administration. 2002. Medical review for NDA 21373. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2002/21-373-Ibuprofen%20Pseudoephedrine-medr.pdf.
68. U.S. Food and Drug Administration. 2000. Medical review for NDA 21128. Accessed July 5, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2000/21-128-CHILDREN'S%20MOTRIN%20COLD%20SUSPENSION-MEDR.PDF.
69. Dykewicz MS, Fineman S, Skoner DP, Nicklas R, Lee R, Blessing-Moore J, Li JT, Bernstein IL, Berger W, Spector S, Schuller D., 1998. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 81: 478-518.
70. Baena-Cagnani CE., 2004. Safety and tolerability of treatments for allergic rhinitis in children. Drug Saf 27: 883-898.
71. Krishna R, Krishnaswami S, Kittner B, Sankoh AJ, Jensen BK., 2004. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride. Biopharm Drug Dispos 25: 373-387.
72. U.S. Food and Drug Administration. 2008. Clinical pharmacology review for NDA 22157. Accessed July 5, 2013, at: http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/ucm072485.pdf.
73. Siegel SC., 1988. Topical intranasal corticosteroid therapy in rhinitis. J Allergy Clin Immunol 81: 984-991.
74. Allen DB., 2000. Systemic effects of intranasal steroids: An endocrinologist's perspective. J Allergy Clin Immunol 106: S179-S190.
75. Sizonenko PC., 2002. Effects of inhaled or nasal glucocorticosteroids on adrenal function and growth. J Pediatr Endocrinol Metab 15: 5-26.
76. Bruni FM, De LG, Venturoli V, Boner AL., 2009. Intranasal corticosteroids and adrenal suppression. Neuroimmunomodulation 16: 353-362.
77. Banov CH, Silvers WS, Green AW, van Bavel JH, Winder JA, Feiss G, Simpson B, Furst JA, Smith JA., 1996. Placebo-controlled, double-blind study of the efficacy and safety of triamcinolone acetonide aerosol nasal inhaler in pediatric patients with seasonal allergic rhinitis. Clin Ther 18: 265-272.
78. U.S. Food and Drug Administration. 2007. Clinical pharmacology review for NDA 22124. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda- docs/nda/2007/022124s000-ClinPharmR.pdf.
79. U.S. Food and Drug Administration. 1999. Review package for NDA 20603-S3. Accessed July 6, 2013, at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 99/20-603S3-InfantsMotrin.pdf.
80. Walson PD, Galletta G, Braden NJ, Alexander L., 1989. Ibuprofen, acetaminophen, and placebo treatment of febrile children. Clin Pharmacol Ther 46: 9-17.
81. Rainsford KD, Roberts SC, Brown S., 1997. Ibuprofen and paracetamol: relative safety in non-prescription dosages. J Pharm Pharmacol 49: 345-376.
82. Lesko SM, Mitchell AA., 1995. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. JAMA 273: 929-933.
83. Lesko SM, Mitchell AA., 1997. Renal function after short-term ibuprofen use in infants and children. Pediatrics 100: 954-957.
84. Lesko SM, Louik C, Vezina RM, Mitchell AA., 2002. Asthma morbidity after the short-term use of ibuprofen in children. Pediatrics 109: E20.
85. Ashraf E, Ford L, Geetha R, Cooper S., 1999. Safety profile of ibuprofen suspension in young children. Inflammopharmacology 7: 219-225.